HC Wainwright Issues Pessimistic Forecast for GPCR Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Equities researchers at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Structure Therapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $114.00 price objective on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.72) EPS, FY2027 earnings at ($2.34) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at ($2.54) EPS and FY2030 earnings at ($2.28) EPS.

GPCR has been the topic of several other research reports. Guggenheim increased their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Citizens Jmp reduced their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Wall Street Zen upgraded Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.90.

Structure Therapeutics Trading Up 0.2%

Shares of GPCR opened at $63.13 on Thursday. The stock has a market capitalization of $4.46 billion, a P/E ratio of -79.91 and a beta of -1.80. The firm’s fifty day simple moving average is $75.10 and its two-hundred day simple moving average is $47.65. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after purchasing an additional 1,150,000 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Structure Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after acquiring an additional 641,322 shares during the period. BVF Inc. IL raised its stake in Structure Therapeutics by 8.6% during the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the period. Finally, Morgan Stanley lifted its stake in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Key Stories Impacting Structure Therapeutics

Here are the key news stories impacting Structure Therapeutics this week:

• Positive Sentiment: HC Wainwright (and coverage reported by other outlets) maintains a Buy rating and a $114 price target, signaling continued analyst conviction in Structure’s pipeline/value despite forecast cuts. Read More.
• Neutral Sentiment: The firm’s valuation backdrop is mixed: market cap ~ $4.46B, negative P/E (losses), a 50‑day moving average above the current price and a 200‑day below — investors are weighing momentum and longer‑term recovery potential. Read More.
• Negative Sentiment: HC Wainwright materially lowered near‑term quarterly EPS forecasts to roughly ($0.43)–($0.44) for Q1–Q4 2026 and cut FY2026 to ($1.72) (previously ~$($1.20)), signaling a weaker earnings trajectory than previously expected; that downward revision is a headwind for the stock. Read More.
• Negative Sentiment: HC Wainwright also trimmed FY2027–FY2030 estimates (FY2027 to ($2.34), FY2028 to ($2.45), FY2029 to ($2.54), FY2030 to ($2.28)), implying the analyst now expects deeper losses farther out — this increases uncertainty around future profitability and potential dilution/financing needs. Read More.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.